Oppenheimer Asset Management Inc. Purchases 2,117 Shares of Repligen Corporation (NASDAQ:RGEN)

Oppenheimer Asset Management Inc. lifted its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 12.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,684 shares of the biotechnology company's stock after buying an additional 2,117 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Repligen were worth $2,505,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Utah Retirement Systems boosted its position in Repligen by 1.1% in the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock valued at $1,338,000 after buying an additional 100 shares during the last quarter. Peapack Gladstone Financial Corp boosted its holdings in Repligen by 5.2% in the fourth quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock valued at $301,000 after acquiring an additional 103 shares during the last quarter. Signaturefd LLC increased its position in Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 124 shares during the period. Arizona State Retirement System increased its position in Repligen by 0.8% in the fourth quarter. Arizona State Retirement System now owns 15,410 shares of the biotechnology company's stock worth $2,218,000 after purchasing an additional 126 shares during the period. Finally, Global Retirement Partners LLC raised its holdings in Repligen by 54.0% during the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 129 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Trading Down 0.5%

Repligen stock traded down $0.65 during mid-day trading on Friday, hitting $123.56. 851,478 shares of the company's stock were exchanged, compared to its average volume of 730,314. The company's 50 day simple moving average is $128.22 and its 200-day simple moving average is $141.22. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $6.94 billion, a P/E ratio of -274.58, a PEG ratio of 3.55 and a beta of 1.10. Repligen Corporation has a fifty-two week low of $102.97 and a fifty-two week high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The company had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. During the same quarter last year, the firm posted $0.28 earnings per share. Repligen's revenue was up 10.4% compared to the same quarter last year. On average, equities analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on RGEN. Royal Bank Of Canada reduced their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 30th. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price objective on shares of Repligen in a research note on Monday, May 5th. Barclays assumed coverage on shares of Repligen in a research report on Tuesday. They set an "overweight" rating and a $150.00 target price for the company. JPMorgan Chase & Co. reduced their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. Finally, Wall Street Zen raised Repligen from a "hold" rating to a "buy" rating in a research note on Saturday, June 21st. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $172.83.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.